Dr. John Shields is an experienced scientist, business executive and venture capital investor. Following 11 years in academia, John joined Glaxo plc before moving to Cantab Pharmaceuticals where he was Senior VP, Research. After 9 years at Cantab, he joined Abingworth LLP, a specialist healthcare and life sciences venture capital company, where he remained for 13 years. For the last 2 years John has been an independent consultant and advisor to a number of venture capital groups, biotech companies and not-for-profit organisations.
John has previously served on the board of several companies including PowderMed, Prosensa, Akubio and Edinburgh BioQuarter. He currently serves on various committees with the MRC, Wellcome Trust, British Heart Foundation, The Crick Institute and Innovate UK.